A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

BACKGROUND: This study investigated the efficacy and safety of a new treatment strategy of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) versus FOLFIRI alone as second-line chemotherapy for metastatic colorectal cancer (mCRC) patients with known V-K...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuguo, Luan, Lijuan, Wang, Xingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437615/
https://www.ncbi.nlm.nih.gov/pubmed/25999741
http://dx.doi.org/10.2147/OTT.S81442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437615/
https://www.ncbi.nlm.nih.gov/pubmed/25999741
http://dx.doi.org/10.2147/OTT.S81442

Ejemplares similares